The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti–CTLA-4 Therapy
Published version of a preprint
Abstract
The anti-CTL-associated antigen 4 (anti-CTLA-4) antibody ipilimumab is the first agent to show improved survival in a randomized phase III trial that enrolled patients with metastatic melanoma. Studies are ongoing to identify mechanisms that elicit clinical benefit in the setting of anti-CTLA-4 therapy. We previously reported that treated patients had an increase in the frequency of T cells expressing the inducible costimulator (ICOS) molecule, a T-cell-specific molecule that belongs to the CD28/CTLA-4/B7 immunoglobulin superfamily. ICOS and its ligand (ICOSL) have been shown to play diverse roles in T-cell responses such as mediating autoimmunity as well as enhancing the development/activity of regulatory T cells. These seemingly opposing roles have made it difficult to determine whether the ICOS/ICOSL pathway is necessary for antitumor responses. To determine whether the ICOS/ICOSL pathway might play a causal role in the antitumor effects mediated by anti-CTLA-4, we conducted studies in ICOS-sufficient and ICOS-deficient mice bearing B16/BL6 melanoma. We show that ICOS(+) T cells comprised a population of Th1 cytokine producing and tumor antigen-specific effector cells. Furthermore, in the absence of ICOS, antitumor T-cell responses elicited by anti-CTLA-4 are significantly diminished, thereby impairing tumor rejection. Our findings establish that the ICOS/ICOSL pathway is necessary for the optimal therapeutic effect of anti-CTLA-4, thus implicating this pathway as a target for future combinatorial strategies to improve the efficacy of anti-CTLA-4 therapy.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ICOS and TIM3 expressions on specific T cells subsets are also related to antitumor immunity.52,53”
From The Diversity of Gut Microbiome is Associated With Favorable Responses to Anti–Programmed Death 1 Immunotherapy in Chinese Patients With NSCLC (2019) · cites this paper as [53]
In the citing paper
“mTORC1 activation has been associated with ICOS expression, a T cell coregulatory receptor seen on tumor-infiltrating T cells that has been associated with clinical response (67).”
From Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis (2019) · cites this paper as [67]
In the citing paper
“In addition, the immune monitoring studies performed on the trial highlighted the reverse translational approach and identified ICOS + CD4 T cells as a novel subset of T cells associated with anti-CTLA4 therapy (17,18,171,172).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [171]
Citations
Cites
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Control of Regulatory T Cell Development by the Transcription Factor Foxp3
Hori, S., Nomura, T., & Sakaguchi, S. (2003) · Science · doi:10.1126/science.1079490 · Cited by 8,187
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
CD28 and CTLA-4 have opposing effects on the response of T cells to stimulation.
Krummel, M. F., & Allison, J. P. (1995) · The Journal of experimental medicine · doi:10.1084/jem.182.2.459 · Cited by 2,245 · cited 1×
“Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) is the prototypical coinhibitory molecule that opposes CD28mediated costimulation (3-5).”
BackgroundCTLA-4 can function as a negative regulator of T cell activation
Walunas, T. L., Lenschow, D. J., Bakker, C. Y., Linsley, P. S., Freeman, G. J., Green, J. M., Thompson, C. B., & Bluestone, J. A. (1994) · Immunity · doi:10.1016/1074-7613(94)90071-x · Cited by 2,222
Sharpe, A. H., & Freeman, G. J. (2002) · Nature reviews. Immunology · doi:10.1038/nri727 · Cited by 1,759
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Harding, F., McArthur, J. G., Gross, J. A., Raulet, D. H., & Allison, J. P. (1992) · Nature · doi:10.1038/356607a0 · Cited by 1,558
ICOS is an inducible T-cell co-stimulator structurally and functionally related to CD28
Hutloff, A., Dittrich, A. M., Beier, K. C., Eljaschewitsch, B., Kraft, R., Anagnostopoulos, I., & Kroczek, R. A. (1999) · Nature · doi:10.1038/16717 · Cited by 1,482
van Elsas, A., Hurwitz, A. A., & Allison, J. P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.3.355 · Cited by 1,020 · cited 8×
“ICOSCD8T cells produce IFN-γ upon recognition of tumor antigen and the absence of ICOS results in diminished tumor antigen-specific T cell responses Since CD8 T cells have been shown to play a dominant role in tumor rejection in the B16/BL6 melanoma model treated with anti-CTLA-4 (7-9, 36), we investigated the impact…”
BackgroundMethodResultInfluentialSutmuller, R. P. M., van Duivenvoorde, L. M., van Elsas, A., Schumacher, T. N. M., Wildenberg, M. E., Allison, J. P., Toes, R. E. M., Offringa, R., & Melief, C. J. M. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.6.823 · Cited by 1,008
ICOS co-stimulatory receptor is essential for T-cell activation and function
Dong, C., Juedes, A. E., Temann, U.-A., Shresta, S., Allison, J. P., Ruddle, N. H., & Flavell, R. A. (2001) · Nature · doi:10.1038/35051100 · Cited by 929
Krummel, M. F., & Allison, J. P. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.183.6.2533 · Cited by 923
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 7×
“ICOSCD8T cells produce IFN-γ upon recognition of tumor antigen and the absence of ICOS results in diminished tumor antigen-specific T cell responses Since CD8 T cells have been shown to play a dominant role in tumor rejection in the B16/BL6 melanoma model treated with anti-CTLA-4 (7-9, 36), we investigated the impact…”
BackgroundMethodResultInfluentialIto, T., Yang, M., Wang, Y.-H., Lande, R., Gregorio, J. D., Perng, O. A., Qin, X.-F. F., Liu, Y.-J., & Gilliet, M. (2007) · Journal of Experimental Medicine · doi:10.1084/jem.20061660 · Cited by 686
Checkpoint Blockade in Cancer Immunotherapy
Korman, A. J., Peggs, K. S., & Allison, J. P. (2006) · Advances in immunology · doi:10.1016/s0065-2776(06)90008-x · Cited by 583
Two Functional Subsets of FOXP3+ Regulatory T Cells in Human Thymus and Periphery
Ito, T., Hanabuchi, S., Wang, Y.-H., Park, W. R., Arima, K., Bover, L. C., Qin, F. X.-F., Gilliet, M. F., & Liu, Y. (2008) · Immunity · doi:10.1016/j.immuni.2008.03.018 · Cited by 565
Liakou, C. I., Kamat, A., Tang, D. N., Chen, H., Sun, J., Troncoso, P., Logothetis, C., & Sharma, P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806075105 · Cited by 549
Self-citationFoster, B. A., Gingrich, J. R., Kwon, E. D., Madias, C. A., & Greenberg, N. M. (1997) · PubMed · Cited by 489
Carthon, B. C., Wolchok, J. D., Yuan, J., Kamat, A., Ng Tang, D. S., Sun, J., Ku, G., Troncoso, P., Logothetis, C. J., Allison, J. P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0569 · Cited by 460
Self-citationHerman, A. E., Freeman, G. J., Mathis, D. J., & Benoist, C. O. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040179 · Cited by 459
Roquin represses autoimmunity by limiting inducible T-cell co-stimulator messenger RNA
Yu, D., Tan, A. H., Hu, X., Athanasopoulos, V., Simpson, N., Silva, D. G., Hutloff, A., Giles, K. M., Leedman, P. J., Lam, K., et al. (2007) · Nature · doi:10.1038/nature06253 · Cited by 414
Small, E. J., Tchekmedyian, N. S., Rini, B. I., Fong, L. H., Lowy, I., & Allison, J. P. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-2318 · Cited by 404
Identification of Tyrosinase-related Protein 2 as a Tumor Rejection Antigen for the B16 Melanoma
Bloom, M. B., Perry-Lalley, D. M., Robbins, P. F., Li, Y., El‐Gamil, M., Rosenberg, S. A., & Yang, J. C. (1997) · The Journal of Experimental Medicine · doi:10.1084/jem.185.3.453 · Cited by 401
Maker, A. V., Attia, P., & Rosenberg, S. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.11.7746 · Cited by 342
van Elsas, A., Sutmuller, R. P. M., Hurwitz, A. A., Ziskin, J. L., Villaseñor, J., Medema, J. P., Overwijk, W. W., Restifo, N. P., Melief, C. J. M., Offringa, R., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.4.481 · Cited by 308
Vonderheide, R. H., LoRusso, P. M., Khalil, M., Gartner, E. M., Khaira, D. K., Soulières, D., Dorazio, P., Trosko, J. A., Rüter, J., Mariani, G. L., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0505 · Cited by 301
ICOS Controls the Pool Size of Effector-Memory and Regulatory T Cells
Burmeister, Y., Lischke, T., Dahler, A. C., Mages, H. W., Lam, K., Coyle, A. J., Kroczek, R. A., & Hutloff, A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.2.774 · Cited by 291
Cell intrinsic mechanisms of T‐cell inhibition and application to cancer therapy
Peggs, K. S., Quezada, S. A., & Allison, J. P. (2008) · Immunological Reviews · doi:10.1111/j.1600-065x.2008.00649.x · Cited by 232
Quezada, S. A., Peggs, K. S., Simpson, T. R., Shen, Y., Littman, D. R., & Allison, J. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20080099 · Cited by 220
Chen, H., Liakou, C. I., Kamat, A., Pettaway, C., Ward, J. F., Tang, D. N., Sun, J., Jungbluth, A. A., Troncoso, P., Logothetis, C., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0813175106 · Cited by 218
Self-citationMak, T. W., Shahinian, A., Yoshinaga, S. K., Wakeham, A. C., Boucher, L.-M., Pintilie, M., Duncan, G. S., Gajewska, B., Gronski, M. A., Eriksson, U., et al. (2003) · Nature Immunology · doi:10.1038/ni947 · Cited by 213
Heteroclitic Immunization Induces Tumor Immunity
Dyall, R., Bowne, W. B., Weber, L. W., LeMaoult, J., Szabo, P., Moroi, Y., Piskun, G., Lewis, J. J., Houghton, A. N., & Nikolić‐Žugić, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.188.9.1553 · Cited by 200
Strauss, L., Bergmann, C., Szczepański, M. J., Lang, S., Kirkwood, J. M., & Whiteside, T. L. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.2967 · Cited by 175
Enhancement of CD8+ T Cell Responses by ICOS/B7h Costimulation
Wallin, J. J., Liang, L., Bakardjiev, A., & Sha, W. C. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.167.1.132 · Cited by 155
Melanoma Cells Express ICOS Ligand to Promote the Activation and Expansion of T-Regulatory Cells
Martín‐Orozco, N., Li, Y., Wang, Y., Liu, S., Hwu, P., Liu, Y., Dong, C., & Radvanyi, L. G. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1379 · Cited by 150
Interferon-γ and Cancer Immunoediting
Dunn, G. P., Ikeda, H., Bruce, A. T., Koebel, C. M., Uppaluri, R., Bui, J. D., Chan, R., Diamond, M. S., White, J. M., Sheehan, K. C. F., et al. (2005) · Immunologic Research · doi:10.1385/ir:32:1-3:231 · Cited by 147
The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity
Harada, H., Salama, A. D., Sho, M., Izawa, A., Sandner, S. E., Ito, T., Akiba, H., Yagita∥, H., Sharpe, A. H., Freeman, G. J., et al. (2003) · Journal of Clinical Investigation · doi:10.1172/jci17008 · Cited by 145
ICOS Costimulation Requires IL-2 and Can Be Prevented by CTLA-4 Engagement
Riley, J. L., Blair, P. J., Musser, J. T., Abe, R., Tezuka, K., Tsuji, T., & June, C. H. (2001) · The Journal of Immunology · doi:10.4049/jimmunol.166.8.4943 · Cited by 130
Liu, X., Bai, X., Wen, J., Gao, J., Liu, J., Lü, P., Yin, W., Zheng, P., & Liu, Y. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.9.1339 · Cited by 119
ICOS costimulation: it's not just for TH2 cells anymore
Sperling, A. I., & Bluestone, J. A. (2001) · Nature Immunology · doi:10.1038/89709 · Cited by 79
Watanabe, M., Takagi, Y., Kotani, M., Hara, Y., Inamine, A., Hayashi, K., Ogawa, S., Takeda, K., Tanabe, K., & Abe, R. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.8.5222 · Cited by 59
Fassò, M., Waitz, R., Hou, Y., Rim, T., Greenberg, N. M., Shastri, N., Fong, L. H., & Allison, J. P. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0712269105 · Cited by 58
ICOS Mediates the Development of Insulin-Dependent Diabetes Mellitus in Nonobese Diabetic Mice
Hawiger, D., Tran, E., Du, W., Booth, C. J., Li, W., Dong, C., & Flavell, R. A. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.5.3140 · Cited by 53
Odegard, J., DiPlacido, L. D., Greenwald, L., Kashgarian, M. J., Kono, D. H., Dong, C., Flavell, R. A., & Craft, J. E. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800758 · Cited by 43
Yagi, J., Arimura, Y., Dianzani, U., Uede, T., Okamoto, T., & Uchiyama, T. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.2.783 · Cited by 34
Potent activity of soluble B7RP‐1‐Fc in therapy of murine tumors in syngeneic hosts
Ara, G., Baher, A., Storm, N. E., Horan, T., Baikalov, C., Brisan, E., Camacho, R., Moore, A., Goldman, H., Kohno, T., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10831 · Cited by 34
Zuberek, K., Ling, V., Wu, P. W., Ma, H., Leonard, J. P., Collins, M. A., & Dunussi‐Joannopoulos, K. (2003) · Cellular Immunology · doi:10.1016/j.cellimm.2003.09.002 · Cited by 23
Cited by
Sorted by citations
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Self-citationHallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Self-citationIFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy
Ivashkiv, L. B. (2018) · Nature reviews. Immunology · doi:10.1038/s41577-018-0029-z · Cited by 1,418
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Loss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300
Self-citation
Metadata
- Authors
- Fu, T., He, Q., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- ORCID
- Sharma, Padmanee
- Venue
- Cancer Research
- Published
- 2011-08-11
- Volume
- 71
- Issue
- 16
- Pages
- 5445-5454
- ISSN
- 0008-5472 (ISSN-L)
- 1538-7445
- OpenAlex
- W2141756397
- Cited by
- 243
- References
- 48
- Citations by year
- 2026: 4 · 2025: 9 · 2024: 15 · 2023: 25 · 2022: 19 · 2021: 23 · 2020: 19 · 2019: 14 · 2018: 20 · 2017: 16 · 2016: 14 · 2015: 17 · 2014: 13 · 2013: 21 · 2012: 11
- FWCI
- 7.48
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- CTLA-4 blockade, ipilimumab, metastatic melanoma, B16-BL6 melanoma, antitumor T-cell responses, tumor rejection, CTLA-4, regulatory T cells, autoimmunity
- MeSH terms
- Animals, Enzyme-Linked Immunosorbent Assay, Melanoma, Experimental, Mice, Inbred C57BL, Proteins, Antigens, CD, Lymphocytes, Tumor-Infiltrating, Mice, CTLA-4 Antigen, Inducible T-Cell Co-Stimulator Ligand
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
